Hemorrhagic shock is the result of acute blood loss. Most of the evidence points toward the benefit of replacing blood loss with blood products. However, there are limitations to their use: cost and availability mainly. There is a need to develop non-blood product resuscitation interventions to achieve a similar outcome. We will discuss the evidence driving this push to develop new fluids and will also review the current evidence behind novel products and interventions.